Another ViewMCB only has one analyst, and no estimates were available. Orders were $24.1M, up 57% year over year and also up sequentially. Revenue though fell 6% to $15.8M. Net earnings fell 72% to $0.5M, with stock-based compensation a big factor, along with the revenue decline. Backlog rose to $30.1M from $24.7M, and book to bill was a solid 1.53. New products and recent contracts imply the future will be better than this quarter. The stock took a hit but it is a small company, still up 91% in a year. It remains in an excess cash position and the valuation is attractive. We would consider it buyable for small/micro cap investors. (5iResearch)